Company: QTIWW
Filing Date: 2025-12-29
Form Type: S-1/A
Source: 0001628280-25-058960
Chunk: 14

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-12-29
Form: S-1/A
Chunk 14
---
 force until August 21, 2028 (the “ Initial Term ”). If GMC has met the Minimum Purchase Requirements (as defined below) during the Initial Term, the Gulf Medical Distribution Agreement shall automatically be extended for an additional one-year term. GMC agrees to meet or exceed the purchase requirements and/or revenue goals for the Approved Products set forth in the Gulf Medical Distribution Agreement (the “ Minimum Purchase Requirements ”) during the Initial Term.

Selectively Consider Offshore Marketing Opportunities

Other than as discussed with respect to Saudi Arabia, the Company has primarily focused its resources on the U.S. market. However, QT Imaging did commence some marketing initiatives outside the U.S. Pursuant to the Distribution Agreement (the “ Innovador Distribution Agreement ”) between QT Imaging and Innovador Healthcare (Asia) Pte, Ltd. (“ Innovador ”), dated November 2, 2022, QT Imaging appointed Innovador, based in Singapore, as QT Imaging’s distributor for much of Asia. The territory for the Innovador Distribution Agreement included Singapore, Malaysia, Thailand, Indonesia, Philippines, Myanmar, Vietnam,Cambodia, Laos, Brunei, India, Pakistan, Sri Lanka, Bangladesh, Nepal, Mongolia, Taiwan, Hong Kong, and Macau. Under the Innovador Distribution Agreement, QT Imaging is responsible for developing and manufacturing its products and supporting Innovador’s product registration and sales and marketing efforts, and Innovador is responsible for product registration, market development, sales & marketing, distribution, and service of the QT Imaging products. Under the Innovador Distribution Agreement, Innovador provides QT Imaging with nonbinding forecasts of the volume of QT Imaging’s products it expects to sell each year. Innovador takes possession of any machines it purchases. The initial term of the Innovador Distribution Agreement is three years and is not being renewed. No meaningful sales have yet occurred under the Innovador Distribution Agreement.

#### Our Competitive Strengths
We believe that our competitive strengths include the following:

• The world-wide market for medical imaging is large and it has a potential to expand in the areas where the Company has differentiation:

• a non-ionizing, non-contrast dye injection imaging modality;

• an imaging modality with superior performance as compared to traditional mammogram with respect to specificity (false positive), thus less unnecessary emotional trauma for patients, reduced numbers of invasive follow-up procedures and a reduction of costs for both patient and broader society;

• a lower price point than conventional high-energy imaging equipment;

• the Company’s technology can be deployed to low resources environments (“LRE